Jiang Ying, Wang Xinjie, Wang Zhenyang, Zhang Shengliang, Wang Jianhua, Wang Xianglong, Zhang Yang
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guizhou University of Chinese Medicine, Guiyang City, Guizhou Province, China.
Turk J Gastroenterol. 2025 Feb 4. doi: 10.5152/tjg.2025.24304.
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is a molecularly heterogeneous solid malignancy that carries a dismal prognosis. Tanshinone IIA (Tan-IIA) is involved in the regulation of N6-methyladenosine (m6A) modification and plays an anti-tumor role in HCC, but whether Tan-IIA regulates HCC by mediating m6A modification is unclear.
Cell apoptosis, invasion, proliferation, viability, and stemness were estimated with flow cytometry, transwell, 5-ethynyl-2'-deoxyuridine, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, and sphere-forming assays. Methyltransferase-like 14 (METTL14) and 3 (METTL3) mRNA and protein levels were detected with reverse transcription-quantitative polymerase chain reaction and western blotting. Total m6A levels were measured using an m6A RNA methylation quantification kit. A possible regulation of tribbles pseudokinase-3 (TRIB3) expression by METTL3 in an m6A-modified manner was predicted through RM2Target and SRAMP and verified by m6A methylated RNA immunoprecipitation (MeRIP) and RIP. Mouse xenograft models assessed the action of Tan-IIA in HCC tumorigenesis.
Tanshinone IIA restrained HCC cell viability, proliferation, invasion, and stemness, and induced HCC cell apoptosis invitro, as well as repressed tumor growth in xenograft models. METTL3 and TRIB3 were upregulated in HCC samples and downregulated in TanIIA-treated HCC cells and xenograft tumors. METTL3 facilitated HCC cell viability, proliferation, invasion, and stemness by enhancing TRIB3 mRNA stability through m6A modification. Tan-IIA played its role by downregulating TRIB3, and Tan-IIA mediated TRIB3 expression by METTL3.
Tanshinone IIA restrained HCC progression by regulating METTL3-mediated m6A modification of TRIB3 mRNA, offering evidence to support the clinical translation of Tan-IIA.
背景/目的:肝细胞癌(HCC)是一种分子异质性实体恶性肿瘤,预后不佳。丹参酮IIA(Tan-IIA)参与N6-甲基腺苷(m6A)修饰的调控,并在HCC中发挥抗肿瘤作用,但Tan-IIA是否通过介导m6A修饰来调节HCC尚不清楚。
通过流式细胞术、Transwell实验、5-乙炔基-2'-脱氧尿苷、3-[4,5-二甲基噻唑-2-基]-2,5-二苯基四氮唑溴盐和球体形成实验评估细胞凋亡、侵袭、增殖、活力和干性。用逆转录定量聚合酶链反应和蛋白质免疫印迹法检测甲基转移酶样14(METTL14)和3(METTL3)的mRNA和蛋白质水平。使用m6A RNA甲基化定量试剂盒测量总m6A水平。通过RM2Target和SRAMP预测METTL3以m6A修饰方式对 Tribbles假激酶-3(TRIB3)表达的可能调控,并通过m6A甲基化RNA免疫沉淀(MeRIP)和RIP进行验证。小鼠异种移植模型评估了Tan-IIA在HCC肿瘤发生中的作用。
丹参酮IIA在体外抑制HCC细胞活力、增殖、侵袭和干性,并诱导HCC细胞凋亡,以及在异种移植模型中抑制肿瘤生长。METTL3和TRIB3在HCC样本中上调,在Tan-IIA处理的HCC细胞和异种移植肿瘤中下调。METTL3通过m6A修饰增强TRIB3 mRNA稳定性,促进HCC细胞活力、增殖、侵袭和干性。Tan-IIA通过下调TRIB3发挥作用,且Tan-IIA通过METTL3介导TRIB3表达。
丹参酮IIA通过调节METTL3介导的TRIB3 mRNA的m6A修饰来抑制HCC进展,为支持Tan-IIA的临床转化提供了证据。